Celivarone

Summary

Celivarone (CHEMBL3707403) is a phase-3 clinical-stage small molecule; indicated across 5 conditions including atrial fibrillation and atrial flutter.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 5 conditions
• Clinical trials: 4
• Chemistry: 533.7 Da · C34H47NO4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3707403
Name	Celivarone
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	9807128
Molecular formula	C34H47NO4
Molecular weight	533.7
InChIKey	ZCENNVQCOZQSGH-UHFFFAOYSA-N

SMILES: CCCCC1=C(C2=C(O1)C=CC(=C2)C(=O)OC(C)C)C(=O)C3=CC=C(C=C3)CCCN(CCCC)CCCC

IUPAC name: propan-2-yl 2-butyl-3-[4-[3-(dibutylamino)propyl]benzoyl]-1-benzofuran-5-carboxylate

Also known as: Celivarona, Celivarone, K45001587E, Ssr149744, SSR149744C, UNII-K45001587E, CELIVARONE

Patent coverage: 11 distinct patent families (26 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 16 (62%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
atrial fibrillation	2	MONDO:0004981	EFO:0000275
atrial flutter	2	MONDO:0005310	EFO:0003911
ventricular fibrillation	2	MONDO:0000190	EFO:0004287
ventricular tachycardia	2	MONDO:0005477	EFO:0005306

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE2	3
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00233441	PHASE2/PHASE3	COMPLETED	Placebo Controlled Double-blind Dose Ranging Study of the Efficacy and Safety of SSR149744C 50, 100, 200 or 300 mg OD With Amiodarone as Calibrator for the Maintenance of Sinus Rhythm in Patients With Recent Atrial Fibrillation/Flutter
NCT00232297	PHASE2	COMPLETED	Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of SSR149744c 100 or 300 mg for the Prevention of ventrICular ARrhythmia-triggered Icd interventiOnS
NCT00232310	PHASE2	COMPLETED	Double Blind Placebo COntrolled Dose Ranging studY of the eFficacy and safEty of SSR149744c 300 or 600 mg for the Conversion of Atrial Fibrillation / fluttEr
NCT00993382	PHASE2	COMPLETED	Dose Ranging Study of Celivarone With Amiodarone as Calibrator for the Prevention of Implantable Cardioverter Defibrillator (ICD) Interventions or Death

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).